The Rome Academy of Sciences, chartered by the New York State Board of Regents since 1966, will host a meeting with speaker ...

Delix Therapeutics, a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological disorders, today announced full results from the ...

What is Guillain-Barré syndrome? Guillain-Barré syndrome (GBS) is also called acute inflammatory demyelinating polyradiculoneuropathy (AIDP). It's a neurological disorder in which the body's immune ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient has been dosed with exidavnemab in the EXIST Phase 2a study, in Parkinson's disease patients. Exidavnemab is a ...

Each scholarship is worth $166,174. This means a total of nearly $500,000 is being injected into pushing vital research ...

Nanotechnology is poised to transform neurological disorder treatments by overcoming the blood-brain barrier, enabling ...

Gerald Obermair, who heads the Division of Physiology at the Department of Pharmacology ... explanation for the origins of the severe neurological symptoms in DEE patients." ...

On Tuesday, Alzamend Neuro Inc (NASDAQ:ALZN) said it finished analyzing the final full data set from a nonclinical study comparing brain and plasma lithium exposures between AL001 and lithium carb ...

In 2010, neu­ro­sci­en­tist and for­mer Eli Lil­ly re­search leader Steve Paul start­ed a com­pa­ny that he hoped would spark a rev­o­lu­tion in drug dis­cov­ery, built … ...